Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders.
Autoimmune epilepsy
Cerebellar ataxia
GAD65
Immunotherapy
Limbic encephalitis
Stiff-person syndrome
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 08 2020
15 08 2020
Historique:
received:
17
12
2019
revised:
07
06
2020
accepted:
07
06
2020
pubmed:
21
6
2020
medline:
11
11
2020
entrez:
21
6
2020
Statut:
ppublish
Résumé
We described the clinical and neuroimaging characteristics of seven Chinese patients with anti-GAD65 antibody-associated neurological disorders of whom epileptic seizures were the initial and main symptoms. All patients were given immunotherapy and followed up monthly. The outcome demonstrates that immunotherapy is helpful for non-seizure manifestations of anti-GAD65-associated neurological autoimmunity and is less effective in the treatment of seizures, yet partial responses can still occur in the early stage. Taken together we suggest a trial with immunotherapy in all patients in the early stage of the disease, and in patients with non-epilepsy symptoms in the later stage.
Identifiants
pubmed: 32563127
pii: S0165-5728(19)30671-X
doi: 10.1016/j.jneuroim.2020.577289
pii:
doi:
Substances chimiques
Autoantibodies
0
Immunoglobulins, Intravenous
0
Glutamate Decarboxylase
EC 4.1.1.15
glutamate decarboxylase 2
EC 4.1.1.15
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577289Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None declared.